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Abstract
Purpose/Objectives: To assess feasibility and toxicity of Helical TomoTherapy® for treating anal cancer patients.
Methods: From 2007 to 2011, 64 patients were consecutively treated with TomoTherapy® in three centres for
locally advanced squamous-cell anal carcinoma (T2 > 4 cm or N positive). Prescribed doses were 45 Gy to the pelvis
including inguinal nodes and 59.4 Gy to the primary site and involved nodes with fractions of 1.8 Gy, five days a
week. A positional Megavoltage Computed Tomography was performed before each treatment session. All acute
and late toxicities were graded according to Common Terminology Criteria for Adverse Events version 3.0. Survival
analysis was performed using the Kaplan-Meier method.
Results: Median follow-up was 22.9 months. Fifty-four women and 10 men were treated (median age: 62 years).
Nineteen patients (29.7 %) had T2, 16 patients (25.0 %) T3, and 27 patients (42.2 %) T4 tumours. Thirty-nine patients
(60.9 %) had nodal involvement. Median tumour size was 45 mm (range, 10–110 mm). Seven patients had a
colostomy before treatment initiation. Fifty-seven patients received concomitant chemotherapy (5-FU/cisplatin or
5-FU/mitomycin-based therapy). Forty-seven patients (73.4 %) experienced a complete response, 13 a partial
response or local recurrence, and 11 had salvage surgery; among these, six became complete responders, three
experienced metastatic failure, and two local failure. At least four patients experienced metastatic recurrence
(concomitant to a local failure for one patient). The two-year overall survival was 85.6 % (95 %CI [71.1 %–93.0 %]),
and the one-year disease-free survival, and colostomy-free survival were 68.7 % (95 %CI [54.4 %–79.4]), and 75.5 %
(95 %CI [60.7 %–85.3 %]) respectively. Overall survival, disease-free survival and colostomy free-survival were
significantly better for women than men (p = 0.002, p = 0.004, and p = 0.002 respectively). Acute grade ≥3 toxicity
included dermatologic (46.9 % of patients), gastrointestinal (20.3 %), and hematologic (17.2 %) toxicity. Acute
grade 4 hematologic toxicity occurred in one patient. No grade 5 event was observed.
Conclusions: TomoTherapy® for locally advanced anal cancer is feasible. In our three centres of expertise, this
technique appeared to produce few acute gastrointestinal toxicities. However, high rates of dermatologic toxicity
were observed. The therapeutic efficacy was within the range of expectations and similar to previous studies in
accordance with the high rates of locally advanced tumours and nodal involvement.
* Correspondence: veronique.vendrely@chu-bordeaux.fr
J. P. Maire Deceased.
ˆDeceased
1Department of Radiation Oncology, Hospital Haut-Lévêque, CHU Bordeaux,
Pessac, France
7Service de Radiothérapie, Hôpital Haut Lévêque, avenue de Magellan, 33604
Pessac Cedex, France
Full list of author information is available at the end of the article
© 2015 Vendrely et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Vendrely et al. Radiation Oncology  (2015) 10:170 
DOI 10.1186/s13014-015-0477-6
Background
Squamous-cell carcinoma of the anus is a rather rare
malignancy, accounting for 2 to 4 % of gastrointestinal
(GI) malignancies, often occurring in elderly women
[1, 2]. However, anal cancer incidence has been in-
creasing over the past decades. Lymphatic spread is
frequent (inguinal and iliac nodes) but metastatic evolu-
tion is rare [3–5]. Since the publication of Nigro et al., the
current standard of care consists of chemoradiation,
which is highly effective, achieving locoregional control
and preservation of anal function without colostomy
[6]. Recurrence (20–30 % of patients) is most often
locoregional, with more than 80 % occurring within
two years of treatment [7–11]. However, delivery of
radiotherapy results in significant acute toxicity (der-
matologic, GI, hematologic, and genitourinary) because
of the large and complex volume to treat and the prox-
imity to critical structures. This important toxicity
sometimes leads to treatment interruptions [12]. There-
fore, many institutions now use intensity-modulated
radiotherapy (IMRT) in order to achieve a better plan-
ning target volume (PTV) coverage, and a better pro-
tection of organs at risk (OARs), allowing reduction of
acute and late toxicities [13–15].
In July 2005, the French National Cancer Institute
(INCa) launched a pilot project to study the medical im-
pact of implementing emerging technologies in radiation
oncology. This led to the installation in 2007 of three
TomoTherapy® (Accuray Incorporated, Sunnyvale, CA)
units in France. Before the units were operational, and
since no published data on TomoTherapy® was available,
treatment indications were validated based on available
IMRT literature. Treatment protocols were devised for
several diseases including anal canal carcinomas, for
which we expected that IMRT using TomoTherapy®
could reduce toxicity by effectively dealing with the
complex volume to treat [16].
This work is a prospective observational study,
reporting the largest published series of patients
treated by TomoTherapy® for anal cancer. The primary
objective was to evaluate the tolerance to chemoradio-
therapy with TomoTherapy®. Secondary objectives
were to evaluate overall survival (OS), disease-free
survival (DFS), colostomy-free survival (CFS), and
prognostic factors of recurrence.
Methods
We included all consecutive patients treated with
TomoTherapy® for squamous-cell carcinoma of the anus
between June 2007 and December 2011 in Bordeaux
(Bergonié Institute and Bordeaux University Hospital)
and in Nantes (René Gauducheau Centre), France.
Institutional review board approval was obtained for
this pilot study.
Inclusion criteria
Treatment indications included locally advanced
squamous-cell carcinomas, T2 larger than 4 cm, T3,
T4 or positive lymph nodes. For these locally ad-
vanced cancers, it is recommended to treat inguinal
and iliac (internal and external) lymphatic areas. All
patients underwent a physical examination including
anuscopy with biopsy and rectal examination, a com-
puted tomography of the chest, abdomen, and pelvis; and
a magnetic resonance imaging of the pelvis. A positron
emission tomography scan was not routinely carried out
for patient staging. Only patients presenting a negative
serology for Human Immunodeficiency Virus infection
were included.
Chemoradiotherapy
Doses prescribed were 45 Gy to the lymphatic areas at
risk (inguinal, mesorectal, and internal and external
iliac), and 59.4 Gy to the tumour and the involved nodes
with fractions of 1.8 Gy, five days a week. A break in
fractions at 45 Gy was introduced in case of toxicity,
however this was not mandatory. Chemotherapy in-
volved a combination of cisplatin and 5-FU on weeks
one and five. This regimen was the standard regimen
for anal cancer treatment in France at that time, and
was also used for the control arm of another French
trial (ACCORD 03 trial) [17].
Target delineation and TomoTherapy® planning
Patients were in supine position with knee and foot
support. CT scans were performed with contiguous
2.5-mm-thick slices with and without contrast infu-
sion. Delineation was performed by a radiation oncolo-
gist and included the following target volumes: the
gross tumour volume (GTV: primary tumour and in-
volved nodes) and the clinical target volume (CTV:
GTV and lymphatic areas at risk: inguinal, mesorectal,
and the internal and external iliac areas). Rules for the
delineation of the CTV were as follows: delineation of
obturator, external and internal iliac lymphatic areas
including vessels plus a 7 mm margin modified by ex-
clusion of bones and muscular structures, inclusion of
the totality of the mesorectum and presacral area, and
inclusion of ischio-rectal fossa and anal margin. In-
guinal areas included inguinal vessels and all visible
groins. In case of anal margin involvement, perianal
skin was included with a wide margin of 2 cm. In case
of posterior vaginal involvement, the entire vagina was
included in the CTV. A 10 mm isotropic margin was
added to CTV and GTV to create PTV1 and PTV2,
respectively. The following OARs were delineated:
bladder, genitals, femoral heads, and intestines. The
dose was prescribed to the median PTV, with 95 % of
the volume receiving at least 95 % of the prescribed
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dose, 98 % of the volume receiving at least 90 % of the
prescribed dose, and 3 % of the volume receiving less
than 107 % of the prescribed dose. Dose constraints
were defined for femoral heads (D2% <40 Gy), bladder
(D2 % <45 Gy, V30 < 20 %), genitals (D2% <50 Gy,
V40 < 60 %), and intestines (D2 % <50 Gy, V30 < 20 %).
The usual planning parameters were a 2.5 cm field
width, a 0.3 pitch and a planned modulation factor of
2–2.5. Some additional dummy structures were delin-
eated such as upper and lower volumes to constrain
the dose gradient outside the PTV. Dummy volumes
were also created between each separate target vol-
umes. During plan optimization, the first priority was
PTV coverage, and then the doses to the OARs and
normal tissues were lowered as much as possible with-
out compromising PTV coverage. Quality assurance
consisted of in-phantom verification and in-vivo dosim-
etry using plain film and ion chamber measurements
before the first fraction of each treatment and before
any treatment plan modification to correlate actual
dose and planned dose.
Clinical course and follow-up
All patients were monitored weekly for acute hematologic,
dermatologic, GI (diarrhoea and nausea), and urinary
toxicity. After completion of the treatment, all patients
were evaluated by a radiation oncologist within six to
eight weeks, every four months for the following two
years, and every six months during the three following
years. All acute and late toxicities were graded according
to Common Terminology Criteria for Adverse Events,
version 3.0 (CTCAE V3).
Statistical analysis
Survival was estimated using the Kaplan-Meier method
from the date of initiation of radiotherapy. OS was de-
fined as time to death, DFS and CFS were defined as
time to progressive disease or recurrence or death and
time to colostomy or death, respectively. All patients
who did not experience the event of interest were cen-
sored at the last follow-up date. Log-rank test was used
to determine factors associated with OS, DFS and CFS.
Associations between violation of the OAR dose con-
straints and acute toxicities were estimated using Fisher
exact test. All analyses were performed using SAS soft-
ware (version 9.2; SAS Institute Inc., Cary, NC, USA). A
2-sided P value of less than 0.05 was considered statisti-
cally significant.
Results
Patient and tumour characteristics
Sixty-nine patients were consecutively treated between
July 2007 and November 2011 (first day of radiotherapy)
for anal cancer: among them five patients presented
with metastatic disease and were excluded. In total 64
patients with locally advanced anal cancer were in-
cluded and analysed. There were 10 men and 54
women; median age was 62 years (range, 32–89 years).
Median tumour size was 45 mm (range, 10–110 mm)
and 67.2 % of these tumours were T3 or T4 tumours.
Sixty-one percent of the patients had lymph node in-
volvement. A colostomy was needed prior to treatment
for seven patients (10.9 %) (Table 1).
Treatment characteristics and dosimetric parameters
Median total dose was 59.4 Gy (range, 45.0–67.1 Gy)
and median dose per fraction was 1.8 Gy (Fig. 1). Dosi-
metric parameters concerning PTV coverage and con-
formity index are summarized in Table 2 and results of
dose volume histogram (DVH) analysis for OARs are re-
ported in Table 3. Median overall treatment time
(OTT) was 57 days (range, 35–113 days). Thirty pa-
tients experienced a treatment break of a mean dur-
ation of 5.9 days: in two centres, the treatment break
was indicated only based on toxicity for 12 patients
whereas in the third centre the break was prospectively
planned for 18 patients. Chemotherapy was combined
with radiotherapy for 57 patients (89.2 %) and
consisted of cisplatin and 5-FU for 49 patients,
Table 1 Patient and tumour characteristics (N = 64)
Characteristic Number Percent
Age, years, median (range) 62 (32–89)
Female gender 54 (84.4)

















Colostomy prior to treatment 7 (10.9)
Data are shown as number (percentage), except when specified otherwise
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mitomycine and 5-FU for three patients. For five pa-
tients, a combination of eloxatine and 5-FU (folfox
regimen) or oral 5-FU in the form of capecitabine were
prescribed because of cardiac or renal comorbidities
(contra-indication for cisplatin). Seven patients did not
receive any concomitant chemotherapy because of co-
morbidities and age.
Clinical outcomes
Sixty-four patients were evaluated at the first follow-up
visit: 34 (54.0 %) had complete response and 30 patients
had partial response at the first follow-up visit (median
interval, 1.6 months; range, 0.4–5.7 months). Eighteen
patients who were considered partial responders at first
follow-up evaluation were considered complete re-
sponders at the following evaluations (up to 14.2 months
after the end of treatment). The median interval between
end of radiotherapy and end of follow-up was 22.9 months
(range, 3.5–52.0 months). Forty-seven patients (73.4 %)
experienced a complete response and 17 patients experi-
enced recurrence after a median 5.4 months following the
end of radiotherapy (range, 3.2–9.3 months): three pa-
tients had distant recurrence, one patient experienced
both local and distant recurrence and 13 patients experi-
enced local failure as first recurrence. Among these 13 pa-
tients, 11 were considered partial responders and two
Fig. 1 Dose distribution on planning CT with Tomotherapy for the first plan of treatment (45 Gy) for a patient with anal cancer
Table 2 Dosimetric parameters (N = 64)
Mean (SD)
Planning Target Volume 1
Dose, Gy 44.04 (5.60)
Conformity Index (opt =1) 1.00 (0.39)
CO (opt =1) 0.93 (0.03)
HI (opt = 0) 0.12 (0.13)
Planning Target Volume 2
Dose, Gy 60.36 (2.92)
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were considered complete responders at first evaluation,
before diagnosis of disease progression. Eleven patients
had to undergo salvage surgery consisting of abdomino-
perineal resection: among them, seven were in complete
remission, two experienced local failure, one experienced
distant failure, and one experienced both local and distant
failure. Overall, six patients experienced metastatic failure,
and for three patients it was the only recurrence. Among
the 17 patients who experienced local or distant recur-
rence, two patients did not receive concomitant chemo-
therapy and four patients had a modified chemotherapy
regimen (eloxatine based regimen for three patients and
capecitabine alone for one patient). Nine patients (14.1 %)
died during follow-up, at a median 11.5 months (range,
5.4–28.7 months). One-year OS was 88.4 % (95 %CI
[75.9 %–94.7 %]) and two-year OS was 85.6 % (95 %CI
[71.1 %–93.0 %]) (Fig. 2). OS was significantly better for
women than men (p = 0.0017) (Fig. 3). OS was not associ-
ated with age, tumour size, nodal status, break in treatment,
concomitant chemotherapy or overall treatment time
(longer or shorter than 56 days).
Among the 57 patients without colostomy at inclusion,
ten patients (17.5 %) underwent colostomy, at a median
of 6.5 months (range, 4.2–13.1 months). One-year CFS
Table 3 Doses to critical organs (N = 64)
Dose Volume Histogram for organs at risk Mean SD Minimum Median Maximum
Genitalia
D98 % 15.69 8.39 2.80 13.52 40.23
D2 % 40.53 12.67 18.63 37.94 66.82
Mean D 24.76 9.82 10.48 22.05 58.10
V40 (%) 14.92 23.06 0.05 5.58 98.27
V40 (cm3) 4.78 5.46 0.04 3.55 23.22
Volume (cm3) 78.40 65.62 10.98 58.54 271.2
Right Femoral Head
D98 % 19.29 7.43 2.42 18.71 47.25
D2 % 39.63 4.86 27.37 40.57 50.07
Mean D 26.90 5.07 15.68 26.47 43.60
Volume (cm3) 112.50 50.98 32.30 122.60 209.20
Left Femoral Head
D98 % 20.31 6.30 4.12 20.50 40.28
D2 % 39.96 5.02 26.93 40.70 49.36
Mean D 27.38 5.28 15.14 27.44 43.41
Volume (cm3) 108.00 53.02 16.80 114.40 207.40
Bladder
D98 % 19.78 5.32 10.45 19.40 33.31
D2 % 51.56 5.90 39.20 50.67 64.83
Mean D 32.18 7.39 22.19 30.73 51.63
V30 (%) 50.11 25.12 9.40 46.38 99.80
V30 (cm3) 65.68 61.91 15.33 45.02 357.70
Volume (cm3) 141.9 132.80 45.50 94.51 635.20
Intestine
D98 % 5.45 5.13 0.50 3.50 19.20
D2 % 45.27 9.17 3.74 45.65 57.47
Mean D 20.64 6.63 1.54 21.69 31.03
V30 (%) 23.50 10.45 4.06 22.17 42.86
V30 (cm3) 219.30 123.00 41.90 187.50 580.60
volume (cm3) 863.20 512.00 231.00 713.50 2295.00
SD, standard deviation
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was 75.5 % (95 %CI [60.7 %–85.3 %]), and CFS was sig-
nificantly better for women than for men (p = 0.0036)
(Fig. 4). There was a trend for increased median age
among men (66 years vs. 62 for women), there was no
difference in terms of size of tumours between genders,
there was a trend towards more frequent treatment
break among men (60 % of men experienced a break in
treatment vs. 44 % of women), and 4 men (40 %) did
not receive concomitant chemotherapy (vs. 5.6 % of
women; p = 0.01).
Seventeen patients (26.6 %) presented progressive dis-
ease or recurrence, at a median of 6.8 months (range,
3.2–16.1 months). One-year DFS was 68.7 % (95 %CI
[54.4 %–79.4 %]) among the entire population, and
women presented a significantly better DFS than men
(p = 0.0019) (Fig. 5).
Toxicity
Acute toxicities are summarized in Table 4. A Grade ≥3
acute GI toxicity (such as diarrhoea), occurred in 20.3 %,
Fig. 2 Kaplan Meier estimates of overall survival (n = 64)
Fig. 3 Kaplan Meier estimates of overall survival according to gender (n = 64)
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grade ≥3 of acute skin toxicity (dermatitis) in 46.9 %
and grade 3 hematologic toxicity in 17.2 % of patients.
One patient experienced an acute grade 4 hematologic
toxicity. A break in treatment at 45 Gy became neces-
sary for 30 patients and mean duration of the break
was 5.9 days (range, 0–23 days). Analysis of the rela-
tionship between violation of the OAR dose constraints
and grade 3 or higher acute toxicity indicated a positive
association between bladder V30 > 20 % and occur-
rence of an acute grade 3 bladder toxicity (83.3 % vs.
0.0 %; p = 0.008).
Discussion
Several studies have demonstrated the dosimetric ad-
vantages of IMRT over 3D conformal radiotherapy
and some studies suggested a decreased toxicity while
achieving at least equivalent outcomes [14, 18–20].
The present analysis was performed in the context of the
INCa pilot project on the medical impact of implementing
new technologies and resulted in a series of 64 patients
treated for anal cancer with TomoTherapy® at three insti-
tutions. The two-year OS of 85.6 % in our cohort is similar
to recent studies, such as Koerber et al. (87.4 % in the
Fig. 4 Kaplan Meier estimates of colostomy-free survival according to gender (n = 64)
Fig. 5 Kaplan Meier estimates of disease-free survival according to gender (n = 64)
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IMRT group) or Vieillot et al. (89 %) [15, 21]. However
one-year DFS of 68.7 % could seem low compared to re-
cent results in the literature: it is important to note that
our study included locally advanced anal cancers and
that two thirds of tumours were T3–T4 tumours, and
61 % were node positive. One could consider that these
results are in the expected range given the high rate of
locally advanced tumours and nodal involvement. How-
ever the question remains about role and type of con-
comitant chemotherapy since in our study 6 patients
among the 11 partial responders had no chemotherapy
or an adapted eloxatine based regimen because of co-
morbidities. Furthermore, the Cisplatin based chemo-
therapy (standard regimen in France at the time of our
study) could also be responsible for this poor DFS since
superiority of mitomycine and 5-FU has been demon-
strated by the RTOG 98–11 trial [8]. The publication in
2012 of the updated RTOG 98–11 trial results has led
to change the recommended chemotherapy regimen in
France to mitomycine and 5-FU. An interesting point is
the significant association of gender to OS, DFS, and
CFS. Such a difference has already been highlighted in
other trials: male gender has been observed as a poor
prognostic factor in RTOG 98–11 trial and more re-
cently by Koerber et al. [8, 15]. In our study, 10 pa-
tients were men; one was on immunosuppressant
treatment, suggesting this patient might have a more
aggressive form of anal cancer. Median age was higher
for men (66 years vs. 62 for women), there was no dif-
ference in terms of size of tumours. There were some
differences regarding characteristics of treatment that
could explain such a survival difference: 4 men (40 %)
did not receive concomitant chemotherapy (vs. 5.6 % of
women; p = 0.01) and there was a trend towards more
frequent treatment break among men (60 % of men ex-
perienced a break in treatment vs. 44 % of women).
Concerning toxicity, our results are consistent with re-
sults reported by studies involving IMRT [13, 15, 18].
Two grade 4 toxicities were observed: hematologic toxicity
for a patient treated with mitomycine-based chemotherapy
and dermatitis for another patient. The level of hematologic
toxicity we observed was comparable to ACCORD 3 trial
and lower than that in RTOG but this toxicity was also in
part due to chemotherapy [7, 9, 13, 17]. Severe acute GI
toxicity was lower (18 % of patients) compared to the
RTOG study (36 % of the patients). We did not en-
counter a relationship between compliance with the
dose constraints and GI toxicity. This could be ex-
plained by the heterogeneity of intestinal volumes
among patients and the fact that intestinal dose con-
straints were specified in terms of proportion and not
in terms of absolute volume. For instance, in our study,
intestinal volumes ranged from 231–2500 cc (mean,
917 cc) depending on the upper level of the CT scan
and on whether the colon was also contoured along
with the small intestine. The only relationship between
following dose constraints and toxicity was found for
acute grade 3 bladder toxicity and V30 > 20 %, which is
not a usual dose constraint for bladder, but was adopted
in order to minimize the dose to the central pelvic zone.
Rates of dermatologic toxicities were high: 46 % of the
patients suffered from grade 3 skin toxicity, which seems
similar to that reported in other studies except the
RTOG 0529 trial [13]. We must take into account the
fact that we did not define any dose constraint for the
skin, which could be added in the future in order to re-
duce this toxicity. We could also study the possibility
to reduce our set-up margin. However we have to be
cautious, because the skin cannot be avoided when
nodes are just below it or in the case of anal margin ex-
tension, limitation of which could result in failure.
Another crucial point when using TomoTherapy® is
the ability to decrease the overall treatment time (OTT)
by avoiding treatment breaks. In the study by Franco
et al., OTT was 44 days (range 37–55) similar to that
in the RTOG 0529 trial (43 days; range 32–59), which
could have been reduced by the use of IMRT com-
pared to the RTOG 98–11 trial (49 days; range 4–100)
[8, 22, 23]. In our study, OTT was 57 days (range 35–113),
which is related to the higher doses and delivery in
two plans. Thirty patients experienced a treatment
break of a mean duration of 5.9 days. In the two cen-
tres where the break was decided only in case of
toxicity, this break was necessary for 12 patients (26 %
of 46 patients) suggesting that TomoTherapy® could
allow treatment without break for 74 % of patients. In
the study reported by Franco et al., 9 patients under-
went a treatment break (17 %) with a shorter mean
duration (3.9 days) whereas the treatment break was
necessary for 40 % of patients in RTOG 0529 [22, 23].
Several publications have shown a relationship between
OTT and survival for squamous cell carcinomas of the
uterine cervix, oropharyngeal cancers, and anal cancer
Table 4 Distribution of Acute Toxicity (n = 64)
Toxicity Category Toxicity Grade, n (%)
0–1 2 3 4 5
Weight loss 55 (85.9) 8 (12.5) 1 (1.6) 0 (0.0) 0 (0.0)
Nausea / vomiting 54 (84.4) 5 (7.8) 5 (7.8) 0 (0.0) 0 (0.0)
Diarrhea 36 (56.3) 15 (23.4) 13 (20.3) 0 (0.0) 0 (0.0)
Anal mucositis 11 (17.2) 26 (40.6) 27 (42.2) 0 (0.0) 0 (0.0)
Cystitis 56 (87.5) 7 (10.9) 1 (1.6) 0 (0.0) 0 (0.0)
Dermatitis 8 (12.5) 26 (40.6) 29 (45.3) 1 (1.6) 0 (0.0)
Haematological toxicity 47 (73.4) 6 (9.4) 10 (15.6) 1 (1.6) 0 (0.0)
All acute and late toxicities were graded according to Common Terminology
Criteria for Adverse Events, version 3.0
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[12, 18, 24, 25]. However, we did not observe any relation-
ship between break vs. no break or OTT being longer or
shorter than 56 days and OS, DFS or CF, similarly to the
results reported by Dewas et al. [26].
Conclusions
TomoTherapy® in locally advanced anal cancer is feas-
ible. At our three centres of expertise in anal carcinoma,
this technique seems to reduce acute GI toxicity; never-
theless, high rates of dermatologic toxicities remain
prevalent. The therapeutic efficacy is in the range of ex-
pectation and similar to previous techniques taking into
account the high rates of locally advanced tumours and
nodal involvement in the cohort.
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